
AxoGen (AXGN) Stock Forecast & Price Target
AxoGen (AXGN) Analyst Ratings
Bulls say
Axogen is favored fundamentally because 3Q26 showed strong, broad-based demand, with revenue of $75.8 million up 26.2% year over year, gross margin of 74.8%, and net income of $2.3 million, signaling improving operating leverage and a path toward sustainable profitability. Management’s raised FY2026 outlook to at least $290 million in revenue, at least 73% gross margin, and positive free cash flow, supported by Avance coverage near 96% of covered lives, a larger sales force, and breast revenue growing more than 50% to over 60% in 3Q26. The October 1, 2026 BioCircuit acquisition and NerveTape broaden the product set, while early prostate data and plans for market development in 2027 add incremental upside beyond current guidance.
Bears say
Axogen is vulnerable to slower growth because commercial coverage remains heterogeneous, with payer policies that can restrict nerve type, gap length, or anatomy and thus limit surgeon access and procedure volume. It also faces meaningful competitive risk from Integra LifeSciences, Stryker, and Baxter International, since broader adoption could weaken if differentiated off-the-shelf alternatives emerge despite Axogen’s current lead in biologically active processed human allografts. In addition, continued approval for portions of the Avance label depends on confirmatory studies, so delays, unfavorable results, or manufacturing non-compliance could narrow the label and jeopardize the durability of the franchise.
This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.
AxoGen (AXGN) Analyst Forecast & Price Prediction
Start investing in AxoGen (AXGN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About AxoGen (AXGN) Forecast
AxoGen (AXGN) Analyst Forecast & Price Prediction
Start investing in AxoGen (AXGN)
Order type
Buy in
Order amount
Est. shares
0 shares